 ARDSLEY, N.Y.--BUSINESS WIRE--Acorda Therapeutics, Inc. Nasdaq: ACOR today announced that it has entered into a definitive agreement to sell its INBRIJA manufacturing operations in Chelsea, Massachusetts to Catalent for 80 million in cash. In connection with the sale, Acorda and Catalent have entered into a long-term global supply agreement under which Catalent will manufacture and package INBRIJA for Acorda, ensuring an uninterrupted drug supply for Acordas patients and continued adheren 